• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h Ventures Announces SEIS Investment in Innovative mRNA-Based Hearing Loss Treatment Company, CamGene Therapeutics
o2h Ventures Announces SEIS Investment in Innovative mRNA-Based Hearing Loss Treatment Company, CamGene Therapeutics
Apr 5 2024

Cambridge, UK – o2h Ventures is pleased to announce its seed investment in Camgene Therapeutics, a pioneering mRNA medicine company focused on developing cutting-edge treatments for hearing loss.

The World Health Organization (WHO) estimates that approximately 700 million people, or one in every ten individuals, will suffer from disabling hearing loss by the year 2050. The need for effective treatments is more pressing than ever. Current innovations, such as hearing aids and cochlear implants, offer limited enhancement, leaving a significant gap in healthcare solutions.

The success of mRNA technology in the rapid development and production of COVID-19 vaccines, has paved the way for its application in addressing other medical challenges. Also, recently we witnessed the start of the world’s first gene therapy-based clinical trial for hearing loss, led by CamGene co-founder and advisor Professor Manohar Bance. CamGene Therapeutics is using mRNA to produce a proprietary combination of proteins to regenerate and protect cells in the cochlear. The mRNA is delivered by a state-of-the-art lipid nanoparticle tailored for delivery to cells in the ear. 

o2h Ventures invested in CamGene Therapeutics from the human health SEIS fund. It has been instrumental in nurturing the company from its conception, providing not only capital but also strategic resources to facilitate the company’s growth. As the lead investor, o2h Ventures is committed to supporting Camgene Therapeutics in its mission to revolutionize the treatment of hearing loss.

Sunil Shah, CEO of o2h Ventures, said: 

This is a double first for us, it is our First investment into a company developing therapeutics for the ear AND our First investment using LNP’s as an enabling technology.  Arpan is a rare find, he has the depth of science that he learnt in his career at AstraZeneca and a genuine entrepreneurial flair.

Arpan Desai, CEO of CamGene Therapeutics, said:

o2h have been instrumental in helping CamGene develop from an idea into a world-class team of scientists, surgeons and entrepreneurs ready to revolutionize how hearing loss is treated.”

About CamGene Therapeutics:

CamGene Therapeutics specializes in biotechnology, focusing on mRNA-based treatments for hearing loss. Their strategy involves creating an LNP mRNA growth factor genetic medicine. This innovative approach aims to regenerate nerve cells and alleviate inflammation, addressing the root causes of hearing impairment. CamGene Therapeutics’ goal is to not only enhance hearing but also to restore it to its natural levels. To know more about the company, please visit www.camgenetx.com

About o2h Ventures

The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in Pre-Seed and seed-stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare. To know more about our funds, please visit – www.o2hventures.com/funds

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information or to invest in the fund, please visit www.o2hventures.com

Media Contact:

Juhi Shah

Marketing Executive

juhi.shah@o2h.com

Connect with us
  • linkedin
  • youtube
  • email
o2h-ventures
recent press releases
  • o2h-ventures o2h Ventures Makes SEIS investment in Sansanima, A University of Sheffield Spinout Developing Alternatives to Animal Testing 28 May 2025
  • o2h-ventures o2h Ventures Shortlisted for ‘Seed VC of the Year’ at UKBAA Angel Investment Awards 2025 14 May 2025
  • o2h-ventures o2h Ventures Backs Enedra Therapeutics, Targeting Complex Cancers 07 May 2025
o2h-ventures
o2h Ventures Limited
Hauxton House,
The Mill SciTech Park,
Mill Lane, Hauxton
Cambridge
CB22 5HX
07341612481
invest@o2h.com
about
  • about us
  • team
  • portfolio
  • funds
insights and news
  • knowledge hub
  • press releases
  • blog
  • event
  • documents
connect with us
  • linkedin
  • youtube
  • email
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
© 2025 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)